



- **Name:** JAE YONG JOUNG
- **Current Position & Affiliation:** Professor, National Cancer Center, Korea
- **Country:** Korea

• **Educational Background:**

1992.03	1994.02	Gyeongsang National University	Medicine	BS
1994.03	1998.02	Gyeongsang National University	College of Medicine	Medicine M.D.
2002.03	2004.08	Ulsan University Graduate School of Medicine	Medical Science	Master of Philosophy
2005.03	2007.02	Ulsan University Graduate School of Medicine	Medical Science	Ph.D.

• **Professional Experience:**

1998.03	1999.03	Asan Medical Center	Internship	
1999.03	2003.02	Asan Medical Center	Residency	
2003.04	2006.04	National Cancer Center	Public Health Doctor	
2006.04	2008.02	National Cancer Center	Oncology Clinic	Clinical Fellow in Urologic
2008.03	present	Center for Cancer Prevention & Detection, National Cancer Center Staff		

2008.03 2009.07 Urologic Oncology Clinic, Center for Specific Organ
Cancers, National Cancer Center Staff

2009.08 present Center for Prostate Cancer, National Cancer Center
Staff

2010.03 present Genitourinary Cancer Branch, National Cancer Center
Senior Scientist

2012.07 2013.06 Cancer Institute of New Jersey(USA) Overseas
2017.03 present Precision Medicine Branch Senior Scientist

• **Professional Organizations:**

2003 present Korean Urological Association Director

2003 present Korean Urological Oncology Society Director

2021 present Korean Prostate Society Secretary General

2022 present Asia Pacific Prostate Society Secretary General

• **Main Scientific Publications: Publications (Total: 126 SCI: 32 SCI-E: 71)**

2022 SCI-E Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis: JAPANESE JOURNAL OF CLINICAL ONCOLOGY. Online:Published (3.019)

2022 SCI-E Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database: WORLD JOURNAL OF MENS HEALTH. 40:e30~ (5.4)

2021 기|타 The important role of poly ADP-ribose polymerase (PARP) inhibitor in prostate cancer: Korean Journal of URological Oncology. :~ ()

2021 SCI-E Rapid androgen-responsive proteome is involved in prostate cancer progression: BIOMEDICINES. 9(12):1877~ (6.081)

2021 SCI-E The effect of subsequent immunosuppressant use in organ-transplanted patients on prostate cancer incidence: a retrospective analysis using the Korean National Health Insurance Database: BMC UROLOGY. 21(1):112~ (2.264)

2021 SCI-E A comparison of the survival outcomes of robotic-assisted radical prostatectomy and radiation therapy in patients over 75 years old with non-metastatic prostate cancer: A Korean multicenter study: INVESTIGATIVE AND CLINICAL UROLOGY. 62(5):535~544 (2.186)

- 2021 SCI-E Cancer Patients'Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea: *CANCERS*. 13(15):3883~ (6.639)
- 2021 SCI-E Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: *FRONTIERS IN ONCOLOGY*. 11:570077~ (6.244)
- 2021 SCI-E Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement: *UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS*. 39(5):298.e1~298.e6 (3.498)
- 2021 SCI-E 2020 Korean guidelines for the management of metastatic prostate cancer: *KOREAN JOURNAL OF INTERNAL MEDICINE*. 36(3):491~514 (2.884)
- 2020 SCI-E How Does Androgen Deprivation Therapy Affect Mental Health Including Cognitive Dysfunction In Patients with Prostate Cancer?: *World journal of Men's health*. Online:Published